A bispecific antibody (bsAb, antibody that targets two different epitopes) is an up-andcoming type of construct among biologics, with two such therapeutics FDA approved (emicizumab and blinatumomab) and on the market, and many more in clinical trials. While the first reported bsAbs were constructed by chemical methods, this approach has fallen out of favour with the advent of modern genetic engineering techniques, and nowadays the vast majority of bsAbs are produced by protein engineering. However, in recent years, relying on innovations in the fields of bioconjugation and biorthogonal click chemistry, new chemical methods have appeared which have the strong potential to be competitive with protein engineering techniques, and indeed hold some advantages. These approaches offer modularity, reproducibility and batch-to-batch consistency, as well as the integration of handles whereby additional cargo molecules can be attached easily, e.g. to generate bispecific antibody-drug conjugates. The linker between the antibodies/antibody fragments can also be easily varied, and new formats can be generated rapidly. These attributes offer the potential to revolutionize the field. Here, chemical methods for the generation of bsAbs will be reviewed, showing that the newest examples of these techniques are indeed worthy competitors to the industry standard expression-based strategies.